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resumo 
 
 
Este relatório descreve as actividades desenvolvidas no contexto do estágio de 9 
meses realizado na Unidade de Gestão de dados da Eurotrials com inicio em Setembro 
de 2011 e fim em Maio de 2012.  
 
A Eurotrials é uma empresa de consultoria científica que presta serviços à indústria 
farmacêutica e biotecnologia, nomeadamente na condução de ensaios clínicos. 
 No processo do desenvolvimento de um novo medicamento os ensaios clínicos são a 
ferramenta mais importante de forma a verificar a segurança e eficácia da substância. 
 
 A gestão de dados cínicos tem um papel muito importante na condução de ensaios 
clínicos e tem como objectivo gerar dados de grande qualidade e robustos para que 
possam ser analisados. A equipa de gestão de dados participa em actividades que vão 
desde o planeamento do estudo até à sua conclusão. 
 
As principais actividades exercidas no âmbito da gestão de dados foram o desenho do 
caderno de recolha de dados, bem como a criação da base de dados, gestão de 
discrepâncias e padronização de dados. 
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abstract 
 
This report describes the activities undertaken in the context of a Curricular training 
with a duration of 9 months in the Data Management Unit at Eurotrials starting in 
September 2011 and end in May 2012. 
 
Eurotrials is a contract research organization that provides services to the 
pharmaceutical and biotechnology industries, namely clinical trial conduction. 
In the drug development process, clinical trials are the most important tool to verify if 
the drug is secure and effective. 
 
The field of clinical data management has a very important role in clinical trials 
conduction and aims to generate high-quality and reliable data so that it can be 
analyzed. The data management team is engaged in activities ranging from the design 
of the study until their completion. 
 
The main activates performed regarding clinical data management were the design of 
the case report form, database design, discrepancies management and data 
standardization. 
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1. Introduction 
 
This report reflects the work developed during 9 months at Data Management Unit of Eurotrials. This 
curricular training occurred during the second year of the Master’s degree in Pharmaceutical Biomedicine.  
 
 
1.1 Training Objectives 
1.1.1 Primary objectives: 
 To Improve and the knowledge acquired during the degree in biomedical sciences and during the 
Master’s degree in Pharmaceutical Biomedicine; 
 To obtain specific working skills and techniques; 
 To understand the work environment of an organization; 
 Establish an integrated working approach, with the constant communication between clinical trials 
unit and data management unit;  
 To establish working contacts network.  
 
1.1.2 Secondary objectives: 
 Identify and understand the importance of data management in clinical trials context;  
 Develop knowledge and expertise in the data management activities performed throughout clinical 
research including: 
o Understand how clinical data is analyzed and transformed in comprehensive information 
for statistical analysis; 
o Contribute to the implementation of CDISC guidelines in clinical data management at 
Eurotrials;  
o Develop data management plans; 
o Construct annotated CRF, database dictionary and manual; 
o Develop data validation plans; 
o Design, programming and validation of databases; 
o Data entry; 
o Detection of inconsistencies: emission, tracking, receipt and entry of queries; 
o Perform Final quality control for database lock; 
o Export information to database in SAS; 
o Elaborate Tables and listings; 
 
. 
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1.2 Vision of the Host Institution 
 
Eurotrials Scientific Consultants was established in 1995, it is a CRO specialized in clinical research and 
scientific consultancy. It is a privately owned company founded by members of academia, medical 
community and pharmaceutical industry.(1) 
 
At Portugal, Eurotrials is certified and recognized by several institutions and organizations, among them: (1) 
 ISO 9001 quality certification.   
 Innovation Small Medium Enterprise (SME) network COTEC since May 2007.  
 Leading SME: In September 2007, IAPMEI recognized Eurotrials as a leading SME. 
 
The main services provided by Eurotrials are:(2) 
 Research Methodology Consultancy;  
 Feasibility Analysis;  
 Trial Design, Protocol and Case Report Form (CRF) Development and Implementation and 
Monitoring of Clinical Trials;  
 Epidemiology and Late Phase Research Studies and Health Economic Studies;  
 Data Management and Statistics; 
 Regulatory Affairs and Pharmacovigilance; 
 Research and Development Consultancy Services;  
 Medical Writing;  
 Quality Assurance;  
 Teaching and Training Activities 
 
The several activities performed at Eurotrials are represented in the following organizational organogram. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1- Eurotrials Organogram (2) 
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The following organogram represents the structure of Data Management Unit at Eurotrials.  
 
 
Figure 2- Data Management Unit Organogram (2) 
 
The data management team at Eurotrials uses innovative technology in electronic data collection, which 
leads to an effective analysis of the data. The Eurotrials’ data management system has been validated and is 
in strict compliance with regulatory authority guidance’s.(2) 
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2. State of the Art 
2.1 Importance of Clinical Data Management in the Outcome of Drug 
Development 
 
Clinical trials are the most important tool in drug development and those are intent to find the answers to 
the questions proposed at the beginning of the drug development. Therefore it is important to develop the 
appropriate studies and apply the right tools in analyzing the data resultant from clinical trials. This data is 
generated with the goal of proving or disapproving a hypothesis. The quality of the data that is generated in 
clinical trials is very important for the outcome of the drug development and therefore it must be carefully 
collected, managed and reported.  Is in this point that clinical data management is important to collect, 
cleaning, and manage the subject data in compliance with regulatory standards. Its primary objective is to 
generate high-quality data by keeping the number of errors and missing data as low as possible, and thus 
prepare the data for the subsequent statistical analysis.(3) 
For this purpose, it is important to establish a consistent and updated data management plan in each drug 
development, since it is a relevant and important part of a clinical trial  
It is also important to meet all the regulatory and guidance documents applied to data quality and when 
managing clinical data.(3) 
When from the process of data management results high-quality data, the statistical analysis is facilitated 
and the results are more accurate and suitable of the clinical reality. Therefore high-quality data means 
minimal or no misses, but more important it should possess only a certain level of variation between the 
captured data and the real data, that would not affect the conclusion of the study on statistical analysis.(3) 
2.2 Clinical Trials – An Overview 
 
The definition of Clinical Trial, according to the World Health Organization (WHO) is the following: “a clinical 
trial is any research study that prospectively assigns human participants or groups of humans to one or 
more health-related interventions to evaluate the effects on health outcomes. Interventions include but are 
not restricted to drugs, cells and other biological products, surgical procedures, radiological procedures, 
devices, behavioral treatments, process-of-care changes, preventive care, etc.” 
 
Clinical trials are required for five purposes:(4)  
 Guide the drug development and move a drug through it.  
 Gain marketing authorization  
 Investigate a certain property of the drug  
 Select one drug rather than another 
 Guide treatment of individual patients 
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Clinical trials can be classified according to when the study occurs during clinical development or according 
to their purpose.(5) The results of prior studies should influence and shape the plan of later studies. 
Generally study results will lead to a modification of the development strategy.  
Clinical trial development is based in phases, although it is not the most correct description, since it may 
lead to the erroneous notion that trials occur in a sequential mode and that each type of study only occurs 
in one phase and that studies from different phases doesn’t occur at the same time. One type of trial may 
occur in several phases.  Consequently it is important to comprehend that the temporal phases do not 
imply a fixed sequence of studies and for most of drugs the typical sequence will not be appropriate or 
necessary.(5) 
The best way to classify a clinical trial is through objectives, as outlined in the figure 1.  
 
 
 
Figure 3 - Clinical Development (5) 
 
This graph represents the clinical development, with the shaded circles showing the types of studies most 
usually conducted in a certain phase of development, the open circles show certain types of study that may 
be conducted in that phase but are less usual.(5) 
 
 
The first studies that should be performed in a clinical development should identify characteristics of the 
investigational medicine to plan an appropriate development based on this profile.(5) 
 The small and early clinical trials in healthy volunteers provide important information to develop 
appropriate bigger and more definitive clinical trials.  
The first human trials aim to establish a safety profile and tolerability evaluation, as well information 
needed to choose a suitable dosage range and administration schedule for initial exploratory therapeutic 
trials.(5) 
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After the completion and statistical analysis of the exploratory data, confirmatory studies are performed to 
establish an efficacy profile of the drug in certain populations and evaluate the long-term effects of it. These 
studies are generally larger and longer and include more diverse patient population.(5) 
 
2.3 Development Phases and Types of Study 
2.3.1 Phase I (Human Pharmacology) 
This phase starts with the initial administration of an investigational new drug into humans.  
The most typical studies conducted in this phase are the human pharmacology studies; however they may 
be present at other point times during the clinical development. The main goals of these studies usually are 
related with the safety profile and tolerability of the drug; therefore they don’t have therapeutic objectives 
and, as referred previously, may be conducted in healthy volunteers. However drugs that are highly toxic 
are studied in patients to minimize the consequences to healthy volunteers.(5) 
 
Main aspects analyzed during phase I studies:(5)  
- Estimation of Initial Safety and Tolerability: the first studies in humans are usually performed to 
analyze the safety of a medicine and to determine the nature of adverse reactions that can be 
expected. These studies may be performed with a single or multiple dose administration.   
- Pharmacokinetics: the pharmacokinetic profile of drug depends on various factors such as the 
formulation and type of administration. Therefore the preliminary characterization of 
pharmacokinetics is an important objective of Phase I.  The results of these studies will generate 
information about the clearance of the drug and allow the anticipation of possible accumulation of 
parent drug or metabolites and potential drug-drug interactions. Nonetheless, it is important to 
retain that the absorption, distribution, metabolism, and excretion characteristics of a drug 
continue during all clinical development.  
- Assessment of Pharmacodynamics: early pharmacodynamic studies in patients may provide 
information about the activity and potential efficacy of the drug and the dosage regime necessary 
to promote a positive therapeutic response and the dosage for the next.  
- Early Measurement of Drug Activity: these studies are usually carried in later phases, however 
when drug activity may be measured with a short duration of drug exposure in patients, these 
studies are a good tool to decide to continue or not with the clinical development.  
 
2.3.2 Phase II (Therapeutic Exploratory) 
This phase has the main goal to explore therapeutic efficacy in patients and its principal objective is to 
determine the dose(s) and regimen for Phase III trials. Additional objectives may include evaluation of 
potential study endpoints, therapeutic regimens for further studies in later phases.(5) 
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The designs of these studies include concurrent controls and comparison with baseline status for the initial 
trials in this phase; however when the aim is evaluate the efficacy of the drug and its safety for a particular 
indication, then they are randomized and concurrently controlled in a group of patients who are selected by 
very restricted criteria, which makes the study population homogeneous.(5) 
Dose regimes design: Early studies in this phase use dose escalation designs to estimate the dose response 
profile. The dose response profile is confirmed in later studies, thought parallel dose-response designs. (5) 
 
2.3.3 Phase III (Therapeutic Confirmatory) 
These studies are larger and their duration is extended for years, their major goal is to demonstrate, or 
confirm therapeutic benefit, in other words, to confirm if the data obtained from Phase II is correct and that 
the drug is safe and effective for use in the intended indication and population. These are the studies 
conducted to provide an adequate basis that the drug is safe and effective.(5) 
 
2.3.4 Phase IV (Variety of Studies: - Therapeutic Use) 
Phase IV begins after drug’s approval. These studies are not consider necessary for approval but are often 
important for improving and optimizing drug’s use. This kind of studies is related to the approved 
indication.(5) 
 
2.3.5 Methods to Minimize or Assess Bias and improve data quality  
The quality of the information collected during clinical trials may be enhanced through some methods, 
described below.  
- Randomization: in a control trial, this is the preferred means of assuring comparability of test 
groups avoiding or minimizing the possibility of selection bias.(5) 
- Blinding:  is an important method used to minimize the risk of biased study outcomes. Blinded 
studies are controlled trials, where an active control or placebo may be used. When only the 
participant doesn’t known each treatment he/she is on, it is called a single blind, when the 
investigator and sponsor staff who are involved in the treatment aren‘t aware of what treatment 
each patient is receiving, it is called a double-blind.(5) 
 
2.4 Contract Research Organization Market  
 
In the past few years, the pharmaceutical industry has been facing productivity crisis. The investment in   
R&D has been rising, however the productivity and successful development of novel drugs is slowing.(6) 
Curricular training Report in Clinical Data Management 
 
12 
 
On an effort to reduce the costs with R&D, the pharmaceutical industry will increase the use of third 
parties, such as Contract Research Organizations (CRO).  
 
 
Figure 4- Comparison of R&D investment and global output of new molecular entities (NME).(7) 
 
 
CRO is an organization that provides support to the pharmaceutical and biotechnological industries in their 
clinical activities in an outsourced form. CROs have become a major partner of pharmaceutical industry in 
clinical trial activities, providing substantial global capacity to drug developers.  
 
In 2008 the total CRO market was estimated to be 20 billion dollars and it was expected to grow at an 
annual rate of 8.55% to reach 35 billion dollars through 2015. This is due to the fact that now, more than 
ever, pharmaceutical industry needs to implement approaches that allow them to save and capitalize 
financial resources. The conduct of clinical trials are a good example of how a CRO allows a company to save 
money, because CROs complete a study up to 30% faster than those that are conducted in-house by 
pharmaceutical companies.(7) 
Thus CROS and pharmaceutical are becoming major associates with and integration of the strategic 
partnerships to gain a competitive edge in the global business environment.(7) 
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3. Clinical Data Management Activities 
 
3.1 Data Management Plan 
 
The data management plan document (DMP) is a road map to handle the data usually placed before the 
data collection which serve as the authoritative resource, documenting data management practices and 
decisions to be followed in the trial.(8, 9) 
The procedures stated in the DMP needs to comply with all applicable regulatory guidelines, e.g. European 
Medicines Agency  (EMA), Food and Drug Administration (FDA), International Conference on Harmonization 
(ICH), Good Clinical Practices (GCP), national laws as well with Eurotrials standard operating procedures.  
(8)This document includes: 
 The description of the data management staff  
 Functions and authorized tasks of each member of data management staff 
 Tasks to be performed according to the financial contract and the study protocol 
 Primary and secondary trial objectives as defined by the study protocol 
 The software to be used for the clinical data management 
 Rules and procedures for database design and implementation  
 Procedures, rules and conventions for data entry 
 
The DMP is an auditable document often asked for by client or regulatory inspectors, therefore the DMP is 
written professionally and with special consideration. During an audit, the inspectors may seek to verify the 
degree to which the CDM staff adhere to the processes described in the DMP.(8) 
 
 
3.2 Clinical Data Management Systems  
 
Clinical data management systems (CDMS) are large and sophisticated applications that are available as a 
tool for clinical data management activities. Also, these software tools are expensive and need 
sophisticated information technology structure to properly function. In multicentre trials, a CDMS has 
become essential to handle the huge amount of data.(9) 
CDMS’s are designed especially to support clinical data management staff to perform tasks over multiple 
and simultaneous studies. The CDMS’s have an underlying database that is used to store the data collected 
in clinical trials. On top of the database there is a graphical user interface (GUI) screen, checklist or form 
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where CDM staff performs their activities, the CDMS’s will translate these activities into the tables defined 
in the database.(9) 
CDM activities at Eurotrials are performed with these software tools, which support a vast range of data 
management tasks including:(9) 
 Database design 
 Entry screen creation 
 Data entry 
 Data cleaning 
 Data validation through edit checks (automatic and manual) 
 Discrepancy management and query resolution 
 Locking of studies 
 Extraction of data for reporting and analysis 
 
3.2.1 Audit trail 
Audit trial is a secure, computer generated, time-stamped electronic record that allows reconstruction of 
the course of events relating to the creation, modification, and deletion of an electronic record. Audit trail 
of CDM activities is a complex and one of the most important features that CDMS can offer. When using 
CDMS multiple user IDs can be created with access limitation to the data, audit trail ensure that each user 
can only perform the activities assigned to them. When clinical data management procedures require to 
change the original data, the audit trail will keep the track of the old value,, the user ID that made the 
change, the time of change, and the reason to justify the change. Thus, during an audit, auditors can verify 
if the changes to the original data were allowed and accurate.(8, 9)  
 
 
3.3 Case Report Form Design 
 
Although the study protocol is considered the most important document used during a clinical trial, study 
case report forms (CRFs) are of vital importance too. Protocol defines the objectives of the study, usually 
regarding efficacy and safety of a specific Investigational Medicinal Product, being the level of emphasis 
dependent on the phase of the clinical trial.(10) 
The International Conference on Harmonisation’s Guidance for Industry: E6 Good Clinical Practice defines 
the term CRF as, “A printed, optical, or electronic document designed to record all of the protocol-required 
information to be reported to the sponsor on each trial subject.”(11) 
The quality of study data is heavily dependent on the quality of the tool used to collect data. CRF´s are the 
most common tool for data collection; therefore special attention must be given to ensuring that data 
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specified in the protocol are collected accurately and consistently. Also, a well-structured CRF simplifies 
database design, data validation processes and statistical analysis.(8) 
The construction of a CRF receives numerous inputs from sources and departments, among them are data 
management unit, statistics unit, clinical monitoring and regulatory staff, that will ensure that the data to 
be collected with CRF meet the needs of the study from all pertinent perspectives.(9) 
Whatever medium is used for the CRF, paper or electronic, the CRF can only be as good as protocol and 
can´t compensate its inadequacies. Reviewing the protocol is essential since it provides an overview of the 
clinical trial and an assessment of possible impacts in CRF design.(10) 
 
3.3.1General organization of data collection forms 
At Eurotrials in the procedure of designing a CRF, the first decision is related with the structure 
(organization) to be used; forms could be organized on the basis of separate clinic visits or evaluations, with 
all forms being used to a specific visit (Visit 1) separated from the forms of another visit (Visit 2). An 
alternative approach is to base the grouping on integration of similar or identical forms (e.g. forms for all 
vital signs are placed together to be followed by all laboratory forms, which in turn are followed by all forms 
for concomitant medication). By this way, different copies of the same form (for any parameter) to be filled 
in different visits are placed together. An alternative approach, is to combine the previous described 
approaches and have some forms arranged in a visit-by-visit grouping and other forms integrated by type of 
examination, test, of form.(12) 
 
Visit-by-visit format  
The advantages of using a Visit-by-Visit format for data collection forms is that is easier for investigators to 
complete them, especially if the data is recorded on the CRF at the time of patient´s visit. One disadvantage, 
however, of this approach is the difficulty to observe trends in data. For example, a gradually changing 
efficiency parameter may be overlooked as values of each visit are in different sections of the CRF and data 
may not so easily compared if all values were on the same contiguous pages.(12) 
 
Combining similar pages 
Contrarily to Visit-by-Visit format, the advantage of combining of similar pages in the same section of CRF is 
that data monitoring and trend detection are more easily achieved. However, the major problem with this 
approach is the CRF completion that is more difficult, since the necessary forms that must be completed for 
a specific visit are in different sections of the CRF.(12) 
 
Hybrid approach 
In certain occasions, the combining of the previous formats may present an advantage. It may be 
considered important to place specific parameters closely, but the rest of the parameters are formatted by 
Curricular training Report in Clinical Data Management 
 
16 
 
the Visit-by-Visit approach. At Eurotrials this approach is generally used. For example, the concomitant 
medication, adverse events, laboratory parameters sections are designed following the combining 
approach, the measurement of vital signs, administration of treatment or even drug accountability are 
designed considering the Visit-by-visit approach with each of this three last forms being repeated for each 
visit that composes the clinical study.(12) 
 
3.3.2 Content, Presentation and Methodology  
CRF completion is prone to human error. Improving the clarity and ease of a CRF will improve the quality of 
data collected in this document.(8) According to Wright and Haybittle there are three main factors which 
contribute to ensure that a CRF is easily understood and used(13): 
 Content – do you need to collect it? 
 Presentation – are you asking the question correctly? 
 Methodology – what design alternatives are available to avoid/minimise problems that users 
have? 
 
Content 
All data collected in CRFs must be correctly attributable to a subject. Each page or section of CRF that can 
be separated or viewed separately must contain enough identifiers to uniquely identify the data contained 
in the page or section.(8) 
The protocol identifies the data to be collected during the trial to achieve the study objectives and meet 
regulatory requirements. Some studies will legitimately omit a few of the following information, but the 
majority will be included:(10) 
 Date, phase and identification of the trial. 
 Identification of the subject 
 Age, sex, height, weight and ethnic group of the Subject 
 Particular characteristics of the subject (smoking habits, dietary status, fertility/pregnancy status, 
previous treatments) 
 Adherence with inclusion and exclusion criteria 
 Medical History 
 Dose, dosage schedule, administration of medical product, compliance record. 
 Concomitant use of other medicines and non-medicinal interventions/therapy  
 Recording of efficacy and or safety parameters met, date and time 
 Reasons for withdrawal 
 Recording adverse events, description, seriousness, severity, duration, intensity, consequence 
(outcome) and measures taken. 
 
Curricular training Report in Clinical Data Management 
 
17 
 
Presentation 
It is important to anticipate the type of answer that is intended to be given. The types of responses are (10):  
 Open – including text, number, alpha numeric 
 Closed – including binary ant multiple choice 
 Combination – of the open and closed response 
 Analogue scales – alternative rating response 
 
Open responses are used when the answer cannot be predicted and it is provided space for the written 
response.(10) 
Dates and times are usually of open numerical response. Within data management units that conduct 
multinational studies, Date Fields are commonly error prone due to different formats: “DD-MM-YY”; “DD-
MM-YYYY”; “MM-DD-YY”; “YY-MM-DD”. To avoid this type of errors the date fields must be standardised, 
usually to the following date format: “DD-MMM-YYYY”. Also, attention is required to the collection of clock-
time when time fields are required, they should be recorded using the “24-hour” format and not using the 
“a.m.” or “p.m.” format.(10) 
When the fields to be recorded are identifiers or measurements such as pressures, rates, length character 
separators can be useful by anticipating their magnitude (e.g. weight measurement |_|_|,|_| Kg).(10) 
Usually open character field relates to comment fields to collect the reasons for treatment interruption, 
patient withdrawal, patient death or adverse events. The problem with open fields is the difficulty to 
transpose the content in comment field in a way that it can be meaningful analysed.(10) 
 
Closed responses are used when the answer is predicted and a list of options can be provided. The 
advantages of this kind of response are: the clarification of the question meaning the provided list of 
answers and it is simpler to make the choice; it also allows the answer to be automatically compatible for 
computer analysis, and forms of electronic data capture.(10) 
In paper trials the selection method is important, the printed list can be annotated to show the correct 
choice by circling, underlining, ticking or checking boxes or deleting the incorrect choice. Wright and 
Haybittle discover that ticking and checking is the best form filler because it is the fastest form filler and the 
easiest read by data entry.(13) When using eCRF, combination boxes (combo boxes) and check lists are the 
most common closed response types. Frequently the closed responses are coded before stored at the 
database for easier data entry and analysis. The codification of a closed response is done by assigning an 
alpha numerical character to all possible options for a specific answer. The options of closed responses and 
the assigned characters are called codelists.(10) 
 
Combination response extends the range of the closed format by the addition of an open format.  The most 
common example is “Other, specify” which is the last item in a multiple choice list and is used when all 
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possible options are not known or not included in the list of choices. “Other, specify” comes at last in order 
to ensure that all the anticipated options are considered first, that is by process of elimination.(10) 
 
Analogue scales are an alternative rating response. Visual analogue scales (usually horizontal lines of 100 
mm) length) are used to measure an individual´s perception of improvement and feelings. Labels defining 
the range are put at either end of the line and the subject is asked to mark the line at a position which best 
represents their own situation. The data is interpreted by measuring the mark on the line from one of the 
ends. However, analogue scales are difficult to set up, monitor and validate, so it is recommended to 
provide clear instructions for marking the line (if possible with illustrations) and ensure that is exactly 100 
mm  in length on return form the printers.(10) 
 
Methodology 
A CRF flow usually follows the data flow from the perspective of the person filling the form. Furthermore 
data fields are arranged in a manner that is clear and easy to follow. Data that are logically related are 
grouped together whenever possible.(10) This group of data, connected between them, is called ‘’Module’’. 
A CRF is composed by different modules including but not limited to: demography, adverse events, 
concomitant medication and medical history. 
While designing the layout of a CRF, CDM staff is very careful with the format and characteristics, since it 
should be consistently including font size and the use of colour. Attention is also required to the intended 
use of the form. (8) Therefore, in order to enhance readability and understanding as well the desired use of 
the form, the choice of layout and design of a CRF should be based in the following characteristics: (10) 
 Type sizes: 8-12 point 
 Type face: e.g., Times Roman, Helvetica, Ariel, Univers 
 Case: mixed, if text is all presented in upper cases the readability can be reduced between 13-20% 
 Line length: 40-70 characters; very short and very long lines should be avoided. 
 Spacing: when items are less spaced it indicates that are related, more space separate unrelated 
ones, space between lines should be inferior then between words. 
 
3.3.3 Wording 
Besides the layout, attention to wording should also be given when designing a CRF, since the form filler 
cannot interact with the CRF to obtain clarification and may be unfamiliar with the colloquial speech of the 
language used. In order to avoid ambiguities, the following aspects are taken into consideration:(10) 
 Avoid use of words with more than one meaning. 
 Avoid use double negative; it should be used positively worded questions and statements. 
 Avoid use of passive voice, instead use active voice as it links individuals with actions allowing a 
better understanding of CRF by the form filler. 
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 Avoid extending unnecessarily phrases or statements; when possible replace it with fewer words. 
 Avoid leading questions, as subjects may feel intimidated and try to please the investigator. 
 When possible, composed questions should be broken into a series of single questions, by using 
binary questions (Yes/No), orienting the form filler to go to another question if needed. 
 
3.3.4 Minimizing redundancy  
Data based on the same measurement should not be collected more than once, because doing so creates 
unnecessary work for site staff and creates a need to check for consistency between redundant data.(8) 
(9)(10) In the same manner, collection raw of data is usually better than collecting calculated values, 
because raw data is easier to verify from source documents and there isn’t the risk of potential errors 
coming from calculated data from different staff and at different time points. An example could be the 
calculation of Body Surface Area or Body Mass Index, since it can be easily computed by CDM or statistical 
staff and recorded on the central database or on the analysis database.(8) 
 
3.3.5 CRF completion Guidelines 
To ensure that CRFs are completed correctly, those should include clearly stated instructions on the 
associated CRF completion guidelines. These guidelines are used to train site staff and help monitors when 
reviewing data in completed forms. Moreover, CRF completion guidelines encompass instructions regarding 
methods of correcting and changing data.(8) 
Instructions and guidelines on completion should take into account the used data collection method (paper 
versus EDC) and should be adapted to the individuals who will be filling the CRF since these guidelines can 
be very different when CRF is to be completed by study subjects or by study staff, generally CRFs are filled 
by the investigators or study coordinators however patient diaries, questionnaires to assess quality of life as 
well the use of scales. Also paper-based CRFs have printed completion guidelines, while EDC systems may 
use on-line help menus despite of printed guidelines. (8) 
 
 
3.4 Database Design and Specification  
 
Regardless the data capture method, which may be paper, EDC or laboratory instruments, data collected 
from a clinical trial is stored in some kind of computer system or systems. Databases should be designed to 
allow complex data to be cleaned, reviewed and reported.(9) 
A database is simply considered a set of data that is structured. This could be an Excel spreadsheet, a 
Microsoft Access, collection of SAS tables or a set of tables built in one of the traditional relational 
applications such as Oracle.(9) 
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Independently of the software used to store and manage clinical data, the CDM staff can only design the 
structure of the database for each clinical trial after the final version of protocol has been defined and the 
CRF has been drafted.(9) 
The main goal for all databases containing information from clinical trials is to store data accurately. 
Additionally, when designing the database also other aspects are considered, including:(9) 
 Clarity, ease and speed of data entry 
 Efficient creation of analysis data sets for biostatisticians  
 Formats of data transfer files 
 Database application software requirements 
 
Commonly, data capture instruments are defined before database implementation. The different types of 
data capture instruments influence the database design but those don’t completely determine it, since data 
from a given CRF page can be stored in a different number of ways in the database.(9) 
 
3.4.1 Calculated or Derived data 
Data from the CRF based on paper or electronic systems are not the only data related with a clinical study. 
There are internal fields that can be useful and even import to the data processing of data that are 
calculated from other data that are obtained using mathematical expressions or are derived from other 
data using text algorithms or other logic.(9) Examples of calculated data include BMI, when weight and 
height are recorded, or transformation of laboratory units to international standard (IS). Examples of 
derived data are the auto completion of fields when other specified fields are filled or extracting the site 
identifier from the log patient identifier. 
These fields can be calculated or derived in the central database and others are calculated or derived 
posteriorly in the analysis database. At Eurotrials, the CDM staff defines where these values should be 
loaded. If these fields are necessary to discrepancy identification and report generation, the best approach 
is to include them in the central database. However, if these values are only used during analysis there is no 
need to create a permanent storage for them on the central database.(9) 
 
3.4.2 Database structure  
A very important aspect taken into consideration when designing the database is its normalization. 
Database normalization is the process of creating a design that allows efficient access and storage. In some 
CDM systems, database records are closely related to the implemented CRF page. Therefore, few options 
for normalization are available to the CRF designer. Other systems, contrarily to the previous, there is a high 
level of normalization and the designer have no design choices. Finally, there are systems that database 
designer can choose the level of normalization intended.(9) 
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The following tables represent a non-normalized and normalized data storage structure: 
Table 1 - Data stored in a non-normalized or short-fat table  
SUBJID VISIT BPM_1 BPM_2 BPM_3 TEMP_1 TEMP_2 TEMP_3 
01 5 56 60 58 36.8 36.9 37.0 
 
Table 2- Data stored in a normalized or tall-skinny table 
SUBJID VISIT MEASURE BPM TEMP 
01 5 1 56 36.8 
01 5 2 60 36.9 
01 5 3 58 37.0 
 
The normalized version of the table has fewer columns and more rows than the non-normalized version. 
The visual impact of the normalization in the database has led to call to them in CDM jargon as short-fat for 
non-normalized tables and tall-skinny for normalized tables.(9) 
Both types of structures store the data accurately and allow its retrieval for analysis, but the choice impacts 
the data management activities. As example, detecting missing records is easier in non-normalized tables 
but creation of the structures themselves and the related checks are facilitated when using normalized 
structures. The advantages from normalized-tables come from the fewer, uniqueness and clear names of 
the fields that compose the table.(9) 
Generally, clinical data collected in a tabular form is easily transferable to a normalized table. Adverse event 
forms, concomitant medication and lesions assessment are examples of data often collected in a tabular 
way and stored in a normalized way. 
In the example given for the normalized form, each column ‘’BPM’’ and ‘’TEMP’’ record data is different 
between them in format and units. However, normalized forms are so flexible that it allows each column to 
collect data of different types of measurement. This approach is called ‘’hyper-normalization’’. This ‘’hyper-
normalization’’ structure is similar to the Study Data Tabulation Model structure proposed by CDISC (Clinical 
Data Interchange Standards Consortium). Laboratory and vital signs are the typical example of this type of 
normalized form, where one column may give the test name, other, the test result, and another, the units. 
The ‘’hyper-normalization’’ of the example given for a normalized form would result in the following table: 
Table 3 - Data stored in a hyper-normalized table 
SUBJID VISIT MEASURE TEST RESULT UNITS 
01 5 1 HEART RATE 56 BMP 
01 5 1 TEMPERATURE 36.8 
0
C 
01 5 2 HEART RATE 58 BMP 
01 5 2 TEMPERATURE 36.9 
0
C 
01 5 3 HEART RATE 60 BMP 
01 5 3 TEMPERATURE 37.0 
0
C 
Curricular training Report in Clinical Data Management 
 
22 
 
 3.4.3 Database Specification 
The output of the database design process is its specification. The specification for a given study is, at a 
minimum, an annotated CRF. Additionally to the annotated CRF, data definition documentation (DDD) is 
frequently required.(9) 
Annotated CRF is usually a blank CRF that has written on it, by hand or in electronic way, the names of the 
fields, or item associated with each CRF field. In different words the annotated CRF maps each field on the 
CRF with the corresponding variables on the database.(9) The annotated CRF is also clearly marked to show 
how questions are related or grouped into modules or tables. It is also helpful, to make the annotation of 
codelists related to closed fields as well as the annotation of any hidden, internal or derived fields 
associated to each module. Annotated CRF is not only used by database designers. This document will be 
used along CDM activities by different staff including edit checks, edit check designers, entry screen 
designer and those searching for inconsistent data on the database. 
The DDD is a technical document that provides a list of all modules or tables, the fields contained in each 
module, the codelists associated with closed fields and its codification. Also, the attributes for all fields or 
variables are described for type (alphanumeric or numeric), label and size. 
 
3.4.4 Database Validation 
After database design, any existing errors need to be identified and corrected. As the database design is a 
crucial step in conducting a study, the rule of “do and review” is always applied. The objective of this 
procedure is to find all possible errors among the database prior its transition to production 
environment.(9)  
Database validation is important because a poor database design may adversely impact not only data entry 
but also data cleaning, extraction, listing and analysis.(9) At Eurotrials, database design validation is 
performed by a second person that did not participate in the database design, as it is not recommended to 
have the same person doing both tasks.  When the database validation and design is performed by the 
same person the review can be biased. 
It is common, when study data is already available, to test the database with real data. All errors found by 
the reviewer in the validation process are then corrected, being the database updated by the database 
designer.  
In order to ensure that all errors found are duly corrected, a database functionality report is released with 
the findings detected during the database validation and the database update with the corrections 
performed. 
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3.5 Data capture and Data entry 
 
Historically, data capture methods have been restricted by the available technology. However, with the 
considerable improvements on software and hardware, in the last years, technology factors are no longer 
considered restrictive.(14) 
The term ‘’data capture’’ refers to the storage of clinical data onto a database in a consistent, logical fashion 
so that it can be retrieved and searched. Ultimately, data receipt and entry is necessary for a study to 
successfully produce a clinical database of sufficient quality to support or refute study hypotheses.   The 
content of the database should reflect the investigator’s observations collected at the clinical trial site, and 
this process of data collection should not obstruct investigator’s clinical practice.(14) 
Whether a study is a paper-based or EDC, the functionality of the tools, the design of the study and the skill 
sets of staff should be carefully considered.  
 
3.5.1 Workflow 
The flow of data should follow a logical path, although specific processes and steps may vary between 
studies and organizations. Concerning the general workflow of paper-based data entry, the CRF pages 
should be tracked or logged, then entered, cleaned and subjected to rigorous audit/inspection or quality 
control. The workflow for EDC studies may vary according to the CDMS software used and study 
specifications.(8) 
 
3.5.2 Data receipt 
Data may be received through fax transmissions, regular mail, express delivery companies, hand delivery by 
monitors or transferred by other electronic means. All data sent from Monitoring staff must come with a 
transmittal form that describes all the information sent.(8) 
When study data is received, the CDM staff will compare it with the corresponding transmittal form. If the 
study data is according to the description of the transmittal form, then CDM staff acknowledge the receipt 
and send a copy to the Monitoring staff. If the study data is not coherent with the transmittal form, the 
Monitoring staff is contacted to correct the information recorded in the form, either by sending the missing 
study data or sending a corrected transmittal form. This procedure may not be applied if the study data is 
sent directly by the sponsor without passing through monitoring staff. 
3.5.3 Data entry 
When data from a clinical study is captured on paper CRFs, this data must be transferred to a central 
database for final storage. The process of transferring it from paper to electronic storage is called data 
entry.(9) 
Curricular training Report in Clinical Data Management 
 
24 
 
At Eurotrials, data entry is performed manually by trained staff called data entry operators (DEO) who input 
data from a paper CRF onto a central database via pre-set data entry screens using conventional 
keyboards.(14) 
Data entry processes should address data quality. Thus, accurately transcribing the data from the CRF to the 
database is essential. Common errors in transcribing are due to typographical errors or illegibility of the 
value as recorded on the CRF.(8, 9) 
CDM staff use the following methods for studies using paper CRF: 
 Double data entry with third party reconciliation of discrepancies 
 Double data entry with second person resolving discrepancies 
 Single data entry with extensive data checking 
 Single data entry with no review  
 
 Double Data Entry 
In double data entry method, one DEO enters all the data in a first pass, and then an independent second 
DEO enters the data again in another instance of the database. In this technique the two entries are made 
and both are stored in two separate instances in the database. After both passes have been completed, the 
CDMS compares the two DEO’s versions of the data in order to identify and highlight all differences 
between these two versions.(8, 9, 14) Further reconciliation between these two versions may be achieved 
by either two methods: 
 A third person, usually a data manager, after all inconsistencies in data were identified or flagged 
(usually by automatic means presented in CDMS) decides whether there is a clear correct answer 
(one of the entries may have a typo, for example) and if it can be validated and transferred to 
database production area or if there is a discrepancy that must be registered because the data 
value is illegible or is in some other way unclear.(9, 14) 
 The second DEO, usually a more experienced one, calls for a judgement to be made between the 
two conflicting entries, or flagging the inconsistencies for further investigation by CDM staff.  This 
method is known as ‘’heads-up second data entry’’.(9, 14) 
 
Single data entry  
Single data entry is a valid option when there are strong supporting processes and technologies in place to 
identify possible typos or errors because of unclear data.(9) Single data entry methods divide in the 
following:(8, 9) 
 Single data entry with no review – although not recommended, situations may occur where one 
person enters data and the data are not subsequently reviewed.  
 Single data entry with review – one person enters the data and a second person reviews the data 
entered against the source data in order to address concerns of higher error rate.  
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3.5.4 Paper Case Report Forms considerations 
Although specific data entry processes are not mandated by regulatory bodies or suggested by ICH guidance 
documents, data entry processes should be adapted according to the quality level needed for each data 
field.(8) 
Double data entering often gives an error rate of 0.1 to 0.2%, and it is typically used if keystroke errors 
occur or if random errors are likely to have a heavy impact in the analyses (8, 9). Therefore, double data 
entry has long been used without question as a reliable method of transcription. The rationale for applying 
double data entry depends if the increase in accuracy outweighs the expense and the associated time delay 
in entering the data twice onto the system.(14) 
To maximize efficiencies, one approach that can be used is the single-entering all fields related to 
comments or entering long-text fields, since these fields are significantly more difficult to enter accurately 
and are often subjected to a later listing review by CDM staff, being the remaining fields entered with one 
of the methods for double data entering.(14) 
The legibility of a CRF in paper based studies usually carries problems to DEOs, who are trained to 
reproduce the CRF page content onto the database, making no assumptions about the data that they are 
entering. Nevertheless, CDM systems have a feature that allows DEOs to flag any data considered doubtful 
or illegible allowing a later revision by experienced CDM staff, thus reducing input time by DEOs and avoid 
effort duplication.(14)  
 
3.5.5 Data entry screen design 
Data entry screen design is an important factor that has a significant impact in the speed at which data can 
be entered and also in the error rate(8, 14). For paper-based studied, data entry screens should follow the 
pages of the CRF, and may even be designed to appear identical do the paper CRFs. Clearly label entry fields 
and ensuring that entry screens have sufficient space to enter and view expected data, are also strategies to 
consider when aiming data entry errors reduction.(8) Therefore, the greater similarity of the entry screen 
with the CRF page, the easier will be the entry of the data in the correct field by DEOs. Nevertheless, 
experienced DEOs often key very quickly, barely glancing at the data entry screen.(14) 
Another consideration when designing data entry screens is format consistent analogous fields, such as 
dates, along the entry screens, which should be inserted in the same format specified in the CRF. For 
example using “DD-MMM-YYYY” in a single field or “DD”,”MMM”,”YYYY” in three different fields. The latter 
format is vastly used, because it allows the collection of partial dates, the month and year to be collected 
even if the day is unknown.(14) 
In order to reduce errors by DEO’s, the use of codelists in the data entry screen is very frequent as it 
restricts the input of data to a limited number or keyed responses. When fields are associated with 
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codelists, they can be programmed in a manner that if the value entered is different from those specified in 
the codelist, the DEO would be readily notified to rectify the value entered.(14) 
 
3.5.6 EDC considerations  
Although sites are typically entering and cleaning data, CDM activities are needed to guarantee that data is 
being entered and processed properly. These data management actions can include training site staff on 
EDC system or measurement of site progress in data entry.(8) 
The growing adaptation of EDC systems as primary system for data collection has a great impact in the 
training and desired skills for data entry staff. In a traditional data entry method, such as double data entry 
from paper CRFs, the skill emphasis on DEOs is the number of keystrokes made and the training emphasis is 
in the data entry system. Although, for EDC systems utilizing single entry, an overall understanding of the 
study becomes much more important in avoiding data entry errors. When EDC is the selected collection 
method, the data is entered directly onto the database by a member of the investigational team at the 
clinical site. Site staff have the capability to solve potential errors as data is entered, since the discrepancies 
are immediately identified as soon as they are entered.(8) 
3.5.7 Modifying data 
Initial data entry is not the only data entry task performed by data management staff at Eurotrials. 
Posteriorly to the initial data entry, there are changes or corrections that may be performed. The processes 
needed for data correction are well-defined. Corrections are usually performed by CDM staff. Any changes 
after initial data entry, made by any person, are recorded in the CDMS audit trail.(9) The Food and Drug 
Administration (FDA) requires audit trails to record changes made in clinical data (21 CFR Part 11), and it 
should be possible, at any time, to check this audit trial.(15) 
 
 
3.6 Electronic Data Capture  
 
Electronic Data Capture (EDC) systems deliver clinical trial data from the investigation sites to the sponsor 
through electronic means (computer programs) that replaces the paper CRF. The investigational site may 
enter the information directly into screens without first writing it down on a paper CRF. Nevertheless, the 
site may first record the information on paper and then enter it later. In both cases, the paper version of 
the data may be the normal site source documents or special worksheets provided by the sponsor.  
However this paper is not considered a CRF, and therefore it is not sent to the sponsor.(16) 
Good quality EDC systems allow the data management process of the entire clinical trial. Therefore, several 
pharmaceutical and biotech companies have set  goals in terms of the proportion of trials they wish to be 
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performed using EDC, moving from pilot studies to general adoption of this technology, as proof of 
confidence in EDC systems increase. (9, 17) 
EDC systems are optimized for site activities during a clinical trial and typically feature:(9) 
 eCRFs for the entry of data 
 Tools for the sponsor, to raise automatic and manual queries for the discrepancies found while 
reviewing data 
 Tools to allow sites to review and resolve discrepancies  
 True electronic signatures so the investigator can sign-off the data entered in the EDC system  
 Record or patient lock on the data 
 Tools to assist monitoring 
 Reports about patients for the sites and reports for the sponsor about sites 
 A portal that provides information to the sites about the study  
 A variety of ways to extract data for review and analysis. 
 
3.6.1 Differences between Electronic Data Capture and Paper-Based studies 
Important areas that differ between EDC and paper-based studies are the manner in which data will be 
collected, the timeline necessary to prepare for the study and the manner in which collected data will be 
verified. 
 
Data capture methods 
At Eurotrials two approaches are used for collecting data: 
 Online - The EDC method typically uses networked resources to record clinical data in electronic 
forms, which is only stored on a central server.  There is no need to install software on the local 
machines of the clinical sites, and the investigators only need a computer with a browser installed 
and an internet connection. Also, Monitors, CDM staff and Clinical investigators have the 
possibility to access data from patients at any time and at the same time.  This increases the level 
of control which is a great advantage when working in a heavily regulated environment.(8, 17) 
 Offline – the traditional paper-based method for collecting and sending the data. (8,17) 
 
Study development and start-up timelines  
Many of the typical CDM start-up activities for both paper based and EDC studies include: Protocol 
approval, CRF design, CRF annotation, edit-check specification.  The differences in CDM start-up activities 
for EDC studies are based largely on the increased number of tasks that must be completed before the 
study may begin.(8) 
Several activities that haveimpact EDC study development and start-up timelines include(8): 
 Role definition and access to data by authorized staff 
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 EDC system and trial specific training  
 User account management 
 Help desk support for users  
 Preparation of coding dictionaries and processes as needed  
 
Source Document Verification (SDV) 
The FDA has issued requirements for electronic records and signatures in 21 CFR Part 11, which provides 
criteria for considering electronic signatures as equivalent to handwritten signatures.(15) More important, 
conducting SDV on electronic records is the same as paper records. Before the start of an EDC study the 
database needs to be configured to support access, workflows and reporting requirements. Electronic 
records, like paper source records, must me accurate, original, legible, attributable and 
contemporaneous.(8) 
 
3.6.3 Advantages and disadvantages of Electronic Data Capture 
Main EDC Advantages 
 Errors are caught in real-time. EDC alerts the clinical investigator that a suspicious data was 
entered, such as incorrect format or range or even when data is entered inadvertently. The 
investigator is informed immediately through a pop up that a suspicious entry must be verified. 
The final result is that the majority of the queries that would normally be encountered when using 
a paper CRF usually do not occur.(16)  
 EDC systems, unlike paper, are able to get cleaner data up-front requiring less back-end cleansing, 
with the use of programmed heuristic edit checks leading to an highly reduction in the discrepancy 
management effort.(9, 16, 17) 
 Reduction of the time from “last patient last visit” to database lock, as there is no need to perform 
a traditional audit to the database because there is no CRF to compare against the database 
searching for transcription errors.(16, 17) 
 EDC enables investigator’s the submission of their own eCRF pages immediately after the patient’s 
visits, contributing to the general speed of the process and faster submission times. (16, 17) 
 
Main EDC Disadvantages 
Site management with EDC goes beyond the already challenging procedures for paper studies In addition to 
all the regulatory compliance requirements and protocol instruction, sites will need to have electronic 
signature procedures and forms, ongoing training in the EDC application, and be submitted to system 
accounts maintaining procedures.(9) 
 Extensive preparation is required from Data Managers prior to the start of an electronic clinical 
study because it requires more upfront preparation than paper studies. Also, unlike paper CRFs, an 
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eCRF requires that the sponsor provide instruction to clinical investigators on how to use the 
computer program and how to get help if a problem occurs.(9, 16) 
 EDC systems can be complicated and difficult to use by clinical investigators, hindering the 
advantages of EDC systems, so the best way to ensure is by taking a test drive with clinical 
investigators or get into consideration references from clinical investigators that already use these 
systems. Like any other technology, the easier the EDC system is to use, the greater the 
productivity will be across every part of the process.(17) 
 Correction of bugs on the eCRF must be careful planned and performed because it can affect the 
study data already collected, leading to possible data losses or down time on the eCRF for the 
sites.(17) 
 
 
3.7 Data Validation Procedures 
 
The aim of Clinical Data Management (CDM) is to guarantee timely delivery of high-quality data that are 
necessary to comply with good clinical practice (GCP) requirements, statistical analysis and reporting 
requirements. CDM validation activities play a pivotal position within drug development program and have 
a direct impact on the quality of data presented in a New Drug Application (NDA).(18) 
There are always discrepancies and data errors that are introduced into clinical database, no matter how 
careful clinical data is entered or collected. The majority of these data inconsistencies and errors can be 
greatly reduced or even totally eliminated by cautious review and data-validation activities.(8) 
 Data validation is defined as a number of steps needed to turn the original data collected in the CRF into a 
clean/validated database by checking discrepancies and resolving them. These steps should ensure that the 
database is accurate, consistent and a true representation of the patient´s profile. (8, 9, 18)  
 
3.7.1 Defining and Implementing Edit Checks  
Prior any data validation procedure, a Data Validation Plan (DVP) is developed by CDM staff. The DVP list all 
checks to be implemented in order to detect discrepancies in study data. 
 
Discrepancies are any inconsistencies in the clinical data that requires further clarification.(18) 
Discrepancies can be as following:(9) 
 Missing values (e.g., temperature values missing) 
 Simple range checks (e.g., temperature value is not between 36
o
C and 38
o
C) 
 Logical inconsistencies (e.g., no vital signs were collected but temperature has a value) 
 Checks across modules (e.g., concomitant medication has given as solution to an adverse event, 
but no adverse event was recorded in the appropriate section) 
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 Protocol violations (e.g. vital signs were measured after the drug administration, and per protocol 
vital signs should be measured before drug administration) 
 
In order to identify these discrepancies different methods are used by CDM staff: (9) 
 Manual review of data and CRF´s  
 Computerized checks of data using CDM/EDC systems  
 Computerized using external systems using SAS and EXCEL macros. 
 
These checks used to find discrepancies are commonly named as ‘’Edit checks’’. The main goal of edit 
checks is to draw attention to data that are inconsistent or potentially erroneous, which is triggered by data 
that are missing, out of range, unexpected, redundant and incompatible or discrepant with other study 
data.(8) 
The edit check definition is specified in the DVP in order to implement the same checks across all clinical 
data during the course of study.(9,18)  The DVP document usually assumes the form of a table with one row 
per check. Each check row is composed by the following columns: 
 Module(s) where it is stored the data to be checked  
 Type of check (manual or computerized)  
 Check ID (unique ID code) 
 Edit check description and message 
 “Performed” (answer “Yes”/”No”) to be filled by the assigned person: Programmer, if automatic 
check or data manager if manual check  
 “Tested”’ (answer “Yes”/”No”) to be filled by the assigned person that will review/approve the 
programming developed by the Programmer; usually this task is performed by the data manager 
or the quality controller 
The CRF page number(s) and module(s) allow identifying where the value is being checked. To each check is 
attributed an identification code, allowing easy identification of the check. The logic operations of the edit 
check is written in a way that other collaborators can understand; usually symbols are used to abbreviate 
intensions (< lesser-than; > greater-than, = equal; <> different). It is also defined the message that will 
appear when the check finds a discrepancy. The ‘type’ column defines the nature of the check: manual or 
computerized. In each check specified in the DVP it is necessary to guarantee that it was performed by the 
appropriate CDM staff and it is correctly implemented. 
 
3.7.2 Managing Discrepancies  
The discrepancies found in edit checks are reviewed by a data manager familiar with the edit check 
specifications and with the CRF. Most of this discrepancies can be internally solved by CRF inspections and 
related data. The remaining discrepancies are sent to the clinical investigator site as queries for resolution. 
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Discrepancies that can be solved by data management staff are often called self-evident corrections (SECs). 
These corrections are restricted to a predefined list and limited to a specific study.(9) Also, these 
corrections should not imply any changes to actual data or results. Common examples include: 
 Adverse events are recorded in the appropriate section, however the box asking ‘’Are there any 
adverse events?’’ could be not filled. CDM staff can mark the box, however the inverse is not 
allowed 
 Dates occurring in January are accidentally recorded in the preceding year.  When data managers 
don’t have any doubt about the correct year, they can change it. 
 
SECs can be managed either by informing the clinical investigators at the end of study about the changes 
that were made, or at the start of the study, when is provided to the clinical investigators a list with the 
allowed SECs.(9) 
It is important to understand that SECs do not follow specific data entry guidelines. It is necessary to raise 
the discrepancy first. The change in the data is clearly identified and it would be necessary to give the 
reason for change, through this method the correction will be recorded in the audit trial associated with a 
person. (9) 
 
3.7.3 Turning discrepancies into queries 
Any discrepancies that cannot be resolved internally by CDM staff, after thoroughly reviewed, are eligible to 
be sent to the investigator site for resolution. These discrepancies are usually sent in a specific form which 
has different names: ‘’query form’’, ‘’discrepancy clarification form’’ or ‘’data clarification form’’ (DCF). 
These forms have all the same purpose and they present the discrepancy to the investigator in an 
understandable and clear way in order to solve it.(9) A special care should be taken into account with the 
text that describes the discrepancy. Investigation site staff should easily identify the discrepancy that is 
under resolution. Also, when this text is being crafted it should be avoided leading questions. For example 
‘’Was 150 mg the administered dose?’’, instead the message should be ‘’Please clarify what dose was 
administered’’, by this means the investigator staff needs to check the source document and not 
automatically answer ‘Yes’ or ‘No’. 
 
3.7.4 Queries Resolution 
Once issued, the query form is sent to the Clinical Research Associate (CRA), via paper mail, or e-mail, being 
the CRA responsible to its delivery to the study sites. For paper based studies, the investigator staff typically 
answers into a spot on the DCF and posteriorly signs and dates it. DCF should be treated as CRF´s as they 
contain original site data. When a site provides the resolution to a discrepancy on a DCF, they may write a 
paragraph explaining the correct action or justifying the value, and data management staff needs to 
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interpret it in order to identity what action should be taken. Sometimes it is necessary to recheck or resend 
the DCF to the investigator site to clarify the resolution provided, due to problems in interpreting the 
response, or because the resolution still carry some degree of inconsistency.(9) 
Those queries that require a change on data or provide a missing value are applied by a different path from 
the initial data entry, the same path as SECs.(9) 
Not all queries result in data changes; the data may be as it was reported in the CRF, or were not collected 
at the time and nevertheless the responses must be recorded in the discrepancy management system to 
close the discrepancy.(9) 
After changes on data were made during queries resolution process, it is essential to rerun all validation 
rules over the data, as it is very common for data updates to cause some other discrepancy, as part of 
discrepancy resolution.(9) 
 
 
3.8 Database Quality Control 
 
Proof of data quality is essential for meeting regulatory requirements. Thus, data collected during clinical 
trial must have as few errors as possible to support findings or conclusions drawn from that trial.(8) 
At Eurotrials, CDM staff performs database audits to fulfil the Quality Control (QC) procedures planned. 
Commonly for a specific study, the quality control staff do not participate directly in data management 
activities. The first step to assemble a QC plan is to identify the CRFs that should be used (data sample 
definition). Then these CRF pages are collected as well the associated query forms. After that, the data is 
compared with the one stored at the central database. The audit result is usually given as the number of 
errors against the number of fields on the CRF or database (calculation of error rate). Depending on the 
result achieved in relation with the maximum error rate defined in the QC plan, corrective actions may be 
taken (8). Finally, the QC procedures should be documented. 
3.8.2 Data Error Categorization   
Database quality control relies on the assumption that errors found in the database can be categorized in 
the following groups:(8) 
 Error type A: error not leading to misinterpretation of the meaning/value on the study data 
information 
 Error type B: error leading to misinterpretation of the meaning/value on the study data 
information 
 Error type C: any error type B found on study objective variables 
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3.8.2 Data sample definition  
The most frequently used number for database quality control is to audit all the data of 10% of the patients 
that completed the study. According to what was defined in the QC plan, this number can be supplemented 
by a 100% audit of all patients’ safety fields (such as those for Adverse Events) and/or a 100% audit of all 
patients’ key efficacy fields.(8) 
 
3.8.4 Error rate calculation 
Calculating an error rate is a better approach than counting the number of absolute errors because it 
facilitates the comparison of data quality across database tables and trials. 
The error rate is defined as the number of errors detected divided by the total of fields inspected. 
 
The following table represents the acceptable error rates: 
Table 4 - Acceptable error rates 
 Type A Type B Type C 
Single data entry Not applicable ≤0,05 ≤0,02 
Double data entry ≤0,10 ≤0,01 =0,00 
 
3.8.4 Corrective actions 
Any errors found in the database during the quality control are corrected by quality control staff. 
If the error rate of the selected sample does not exceed any of the acceptable error rates, then the 
database quality control is concluded. Otherwise, if at least one error rate is exceeded, a new sample of 
data is selected and the procedure is repeated until the errors found in the selected sample do not exceed 
any of the acceptable rates. In extreme cases, this procedure could lead to an audit to all study data (100%) 
of all the patients that concluded the study. 
 
3.8.5 Documentation 
After the conclusion of database quality control, the study data manager and the data manager quality 
controller will release a database quality control report detailing all errors found in the comparison 
between the study data and the database. Anyone that reads this report should be able to recreate the 
sampling and error rate calculations and produce the exact same results. 
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3.9 Final Database 
 
After the last patient´s data has been collected from the sites and all data is validated, the study database is 
ready to be closed and locked in order to ensure data integrity.  Once the database has been locked, the 
study database is considered final. (8, 9) The last responsibility of CDM staff is to deliver the final database 
to the statistics staff, so that the final statistical analysis can be performed and study conclusions drawn.(8)  
 
3.9.1 Database Closure Procedures 
Closing and locking a study database is of vital importance as it prevents inadvertent or unauthorized 
changes. Although important in open label studies, database closure and lock plays a role even more 
important to preserve the integrity of randomized trials after the blind has been broken. Thus, there is a 
well-defined process for closing the study database, which is followed to ensure that relevant study staff 
have been informed or approved the database lock.(8) 
The preparation for database closure includes the following procedures: 
 All data have been received, processed and validated 
 All queries have been resolved 
 Reconciliation of sponsor adverse event database, if existent, with the main study database 
 Conclusion of database quality control, with acceptable database error rates and documentation of 
the errors that occurred 
 All documentation is updated and stored according to standard operation procedures. 
 
After the conclusion of database closures procedures, the database will be locked by CDM staff and 
considered as the ‘’Final Database’’. Then, a signed certificate by the CDM staff is released (and sent to 
sponsor, if required). As soon as this certificate is signed, edit access to the database is removed to all other 
users by the study data manager. 
 
3.9.2 Errors found after database closure  
After database lock, if an error is found, the sponsor is readily notified. CDM staff along with a statistician 
and/or a medical reviewer evaluates the potential effect of this error on the analysis of safety and efficacy.  
Not all errors found must be corrected in the database itself, being these errors just documented in the 
statistical or clinical report. It is the sponsor who decides to change all errors found in the study database or 
only to change those that have major impact on the safety/efficacy analysis.(8) 
If it is decided to eliminate any error, a listing containing the subject identification, item identification, value 
to be replaced, the new value and the reason for data replacement, will be provided to the CDM staff. The 
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changes performed to the database after the un-lock are documented (and sent to the sponsor, if required). 
Re-locking the database follows the same process for notification as the initial lock. 
 
3.9.3 Randomization code break  
In case of a blind-study, the randomization codes must only be broken after the study database lock. The 
only exception is in the case of a medical emergency. The un-blinding of the randomization codes must be 
authorized by the sponsor. 
The randomization codes are entered by DEO in a specific dataset which is reviewed by CDM staff. This 
dataset is essential to assign the treatment arm with the investigational medical products and comparators 
so that a correct safety/efficacy analysis can be performed.  
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4. Data Standards and CDISC Implementation 
 
 
4.1 Data Management Standards in Clinical Research 
 
The advent of modern information technology has enabled widespread use of comprehensive standards 
that encompass almost every part of data collection and handling.(8) Although there are few regulatory 
mandates for using any particular standard, using standards in all areas of data collection and handling can 
greatly increase an organization´s efficiency by shortening reducing overall time and expenses while 
maintaining consistency for data managers and those charged with collecting data at clinical sites.(8,19) 
Most of the established standards currently in use are readily available and designed to be independent of 
any vendor or platform.(20) 
Although multiple standards exist for similar concepts, the ultimate goal is for researchers everywhere to 
use the same standards and naming conventions for their studies. This goal has not yet been reached, but 
the clinical research industry is trending in that direction. If different parts of an organization can freely use 
whatever data standards as they wish, many of the benefits of standards are lost.(8)  
 
4.1.1 Barriers to Standards Implementation 
There are a lot of wrong assumptions taken by corporations about standards implementation that are 
nothing more than myths, consider the following:(19) 
 Standards stifle creativity 
 Companies have their own way of doing things so standards don’t apply to them 
 Standards are always changing so companies should wait until they stabilize 
 There are too many standards so it is too hard to choose 
 Standards can be implemented at the last minute when required without any change to the 
existing organization 
 There is no good time to implement standards 
 
4.1.2 Purpose and Benefits of Standardization 
Within the context of CDM, standards are used to optimize the collection, transport and storage of data, 
and to simplify the submission of data to regulatory bodies.(8) 
The use of standards within clinical research involves using standardized names, coded, structures and 
formats for data across different locations, studies and organizations. Using the same formats, names and 
codes for different studies can greatly decrease the time and money needed to set up a study, particularly 
in cases where similar studies have been conducted in the past. (20) Standards provide benefits beyond 
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study setup and can also help streamline processes for study conduct, data transfers, analyses and 
regulatory submissions.(19, 20) Ultimately, standards facilitate bringing safe and effective treatments to 
patients in a more timely and cost-effective fashion.(19, 20) 
It is clear that data standard bring more than just savings and a reduced cycle time, but companies may also 
see the following benefits to their organization when they implement standards:(19) 
 Communication among project teams and partners becomes easier, regardless of which part of the 
study they participate. 
 People working within the clinical research environment execute the work with more accuracy and 
less up-front training as the process is consistent and not constantly changing. 
 Decision making becomes simpler, as format or data fields are already pre-specified. 
 Enables the use of different technology/tools as long they are compliant with the same standards 
 Easier transfer of data between partners. 
 
4.1.3Data Standards categories 
Data standards can be divided in the following categories: 
 
Standards Governance – if every part of an organization were free to use any standards they wish, many of 
the benefits are lost. This would end with the proliferation of redundant standards and each part of the 
organization would be forced to develop their own databases and analysis tools. In order to avoid this, an 
organization needs a standards governance structure that specifies what standards will be used by the 
organization. As much as possible the governance board should adopt standards that are widely recognized 
by a broad standards community (e.g. ISO, ANSI).(20) 
 
Exchange Standards – refer to standards for structuring data for exchange between organizations. An 
exchange standard describes how to organize the data for exchange between organizations. An exchange 
standard does not specify what data should be exchanged (content) neither terminology used to describe 
the content.(20) 
 
Terminology Standards – a critical part of any implementation of a data standard is the terminology used to 
describe de data. While data attributes are often described by a single word, a rigorous terminology 
standard requires a concept definition, a code for the concept and a list of labels associated with the 
concept. While different users use different labels for the concept, the concept definition and concept code 
remain unchanged.(20) 
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Content standards – are standards that define what information needs to be exchanged between 
organizations. An organization may need a large amount of diverse content, but a particular user may need 
only a fraction of the data that could be potentially exchanged via the standard.(20) 
 
Reporting and analysis standards – a variety of datasets are needed by different users of the data. Some 
users will need specific static reports, while others will need general purpose datasets that can be used for 
analysis either pre-specified or ad-hoc. Unlike exchange standards, reporting and analysis standards need to 
be tailored to the specific used planned by the end users.(20) 
 
Data acquisition standards – ideally data should be collected in a way consistent with the way it will be 
exchanged. Data should only need to be entered once, recoding should be kept to a minimum and every 
piece of data should be mapped to a location in the implemented standard.(20) 
 
 
4.2 Clinical Data Interchange Standards Consortium Background 
 
Clinical Data Interchange Standards Consortium (CDISC) and was formed solely to create standards for 
clinical/medical research data. In their mission, states “CDISC is a global, open, multidisciplinary, non-profit 
organization that has established standards to support the acquisition, exchange, submission and archive of 
clinical research data and metadata. The CDISC mission is to develop and support global, platform-
independent data standards that enable information system interoperability to improve medical research 
and related areas of healthcare. CDISC standards are vendor-neutral, platform-independent and freely 
available via the CDISC website’’.(21)  
 
CDISC was created in 1997 to address the needs of FDA and biopharmaceutical needs. However, today 
CDISC is making a pronounced effort to ensure that the developed standards are broadly applicable to 
medical research whether it is academic, government-sponsored or for product development.(8,19)  
It is important to refer that since the inception of CDISC, all standards developed were performed by 
volunteers.(8,19) 
CDISC works closely with other standard development organizations such as ISO and HL7. This 
collaborations demonstrate the commitment to improve interoperability among clinical and research 
systems as well as a closer relationship between clinical and research standards.(8, 19) 
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CDISC in order to streamline medical research from the protocol through reporting of results while 
improving data quality and patient safety created many standards such as:(8,19) 
 Clinical Data Acquisition Standards Harmonization (CDASH) – Standard that defines a minimum set 
of data collection fields in CRFs 
  Study Data Tabulation Model (SDTM) – The content standard for regulatory submission of case 
report form tabulations from clinical research studies. 
 Case Report Tabulation Data Definition Specification  – Also known as “define.xml”, defines the 
format and content of specification and attributes of CDISC SDTM datasets. 
 Analysis Data Model (Adam) – The content standard for regulatory submission of analysis dataset 
and associated files. 
 Terminology – The controlled standard vocabulary and code sets for the all CDISC 
model/standards 
 
 
4.3 Study Data Tabulation Model Overview 
 
The Study Data Tabulation Model (SDTM) provides a standard structure for describing information collected 
during clinical trials that are to be submitted as part of a product application to the regulatory 
authorities.(22, 23) The SDTM is used either to submit clinical trial or non-clinical data for product 
application across all therapeutic areas.(22 ,23) The SDTM model has two important ways to provide 
flexibility. First, for each domain/dataset it is defined a superset of variables (an exclusive list) where only a 
small number of variables are required to be present in every submission. Second, the set of 
domains/datasets required to a specific application is not defined by the model but determined with the 
goals and endpoints of the clinical trial protocol.(22, 23) 
 
The availability of defined standard data for submission provides many benefits to the reviewers as they can 
be trained in the principles of standardized datasets and the use of standard software tools, and thus be 
able to work with data effectively with less preparation time.(22, 23) 
 
The SDTM is based on a concept of observations about subjects who participated in a clinical study. An 
observation is described by a series of variables corresponding to a row in a dataset or table.  
Most of the subject-level observations collected during the study are represented in one of the three SDTM 
general observation classes:(22, 23) 
 The Interventions class – captures investigational, therapeutic and other substances that are 
administered to the subject either as specified by the protocol (e.g. exposure to study drug), 
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coincident with the study assessment period (e.g. concomitant medications), or self-administered 
by the subject (e.g. use of alcohol, tobacco or caffeine) 
 The events class – captures planned milestones such as randomization and study completion, and 
occurrences, conditions, or incidents independent of planned study evaluations occurring during 
the trial (e.g. adverse events) or prior to the trial (e.g. medical history). 
 The Findings class – captures the observations resulting from planned evaluations to address 
specific tests or questions such as laboratory tests, ECG testing, and questions listed on 
questionnaires. 
 
Observations about study projects are usually collected for all subjects in a series of domains. A domain is 
defined as a collection of logically related observation with a common topic. In non-standardized studies 
the domain is known as modules. Each domain is represented by a single dataset and is distinguished by a 
unique (except for Relationship Datasets) two character code that is used consistently throughout the 
SDTM.(22, 23) 
There are standard domains and their respective codes that are already defined by CDISC team which falls 
in the following seven categories:  
Table 5 - SDTM Domains(22, 23) 
Special-Purpose Domains 
Demographics - DM Comments - CO 
Subject Elements - SE Subject Visits – SV 
Interventions General Observation Class 
Concomitant Medications - CM Exposure - EX 
Substance Use - SU  
Events General Observation Class 
Adverse Events - AE Disposition - DS 
Medical History - MH Protocol Deviations - DV 
Clinical Events - CE  
Findings General Observation Class 
ECG Test Results - EG Inclusion/Exclusion Criterion Not Met - IE 
Laboratory Test Results - LB Physical Examination - PE 
Questionnaires - QS Subject Characteristics - SC  
Vital Signs - VS DRUG Accountability - DA 
Microbiology Specimen - MB Microbiology Susceptibility  Test – MS 
PK Concentration - PC PK Parameters - PP 
Findings About 
Findings About - FA  
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Trial Design Model 
Trial Arms - TA Trial Elements - TE 
Trial Visits - TV Trial Inclusion/Exclusion Criteria - TI 
Trial Summary - TS  
Relationship Datasets  
Supplemental Qualifiers – SUPPQUAL or multiple 
SUPP-- Datasets 
Related Records - RELREC 
 
When preparing the SDTM for a specific study, only domain datasets that were collected or even derived 
data from the collected data are submitted. The collected data for a specific study can use some or all the 
standard domains developed by CDISC team as well additional custom domains based in three general 
observation classes.(23) 
 
All SDTM variables allowed for each domain are defined. Generally, for each domain the variable is named 
with its two letters code prefix followed by a word fragment, allowing easy identification of the variable 
origin.(22, 23) The SDTM model does not foresees the addiction of custom variables on the existing 
domains. These variables are recorded as values in the SUPP Domain. Furthermore, it is not necessary to 
represent all variables created by CDISC team when submitting SDTM to regulatory authorities. Thus, CDISC 
team created the “Core” concept to aid in variable compliance. The three categories specified are:(23) 
 Required – these variables must always be included in the dataset and cannot be null for any 
record. Required variables are necessary for identification of a data record or to make a record 
meaningful. 
 Expected- these variables are necessary to make a record useful in the context of a specific 
domain. When no data were collected for an expected value, a null column should still be included 
in the dataset, with a comment in the metadata (“define.xml”) stating that data was no collected. 
 Permissible – these variables are used in a domain, as appropriate, when collected or derived. 
When data is not collected for these variables, there is discretion to either include them or not, as 
a column. However, there is no discretion to not submit permissible variables when they contain 
data. 
 
Each variable usually takes place as a column in the dataset and following the SDTM Model is classified in 
the following five major roles:(23) 
 Identifier variables – identify the study, the subject, the domain and the  sequence number of the 
record 
 Topic variables – specify the focus of the observation which vary according to the type of 
observation (laboratory test, medication treatment, or medical history term) 
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 Timing variables – describe the timing of an observation (start date, end date or time of collection) 
 Qualifier variables – include additional text or numeric values that describe the results or 
additional characteristics of the observation (such as units or descriptive adjectives) 
 Rule variables – expresses an algorithm or an executable method to define start, end or looping 
conditions only applicable in the Trial Design model. 
 
Within a domain, CDISC team defined the order of the variables, in order to facilitate the review. Variables 
for the three general observation classes should be ordered with Identifiers first, followed by the Topic, 
Qualifier and Timing variables.(23) 
 
If the following observation example is taken: “Subject 01 had 35 
o
C of temperature starting on day 5”, the 
value for identifier variable is “Subject 01”, the topic variable is “fever”, the qualifier variable “35 
o
C” and 
the timing variable is “starting on day 5”. 
 
Dataset or domains prepared for submission are described by metadata definitions that provides 
information about the variables used for each dataset. The metadata is described on DDD usually named 
“define.xml” and it is submitted with the datasets to regulatory activities.(24) 
The “define.xml” has two main parts: Table of Contents (TOC) and Data Definition Tables (DDT). The TOC 
lists all datasets/domains included in the submission and the DDT describes the variable level attributes, 
definitions and usage information for each variable contained within each domain.(24) 
 
The Table of Contents contains the following fields to describe the metadata of SDTM domains/datasets: 
Table 6 - Define.xml  Table of Contents(24) 
Field Description 
Dataset The name of the domain/dataset (e.g.,”AE”). 
Description A short description of the type of information contained within the domain/dataset 
(e.g., “Adverse Events”). 
Structure The level of detail represented by individual records in the dataset (e.g., “One record 
per subject”, “One record per subject per visit”) 
Purpose Purpose for the dataset (e.g. tabulation) 
Keys Key variables are used to uniquely identify and index record in a domain/dataset. 
Location Folder and filename where the domain/dataset can be found. 
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The Data Definition Table section contains the following fields to describe the metadata of SDTM 
domains/datasets: 
Table 7 - Define.xml Data Definition Table(24) 
Field Description  
Variable The field name of the variable. 
Label A brief description of the variable. 
Type The variable type (Character or Numeric). 
Controlled Terms or Format The set of controlled terms or variable display information. 
Origin Indicator of the origin of the variable (e.g., CRF pages, derived, protocol). 
Role Information on how a variable is used within the dataset (e.g., “Identifier”, 
“Topic”, “Timing”, “Qualifier”, “Rule”. 
Comment Other information regarding the variable definition, usage. 
 
FDA has referenced the use of the SDTM in the Study Data Specifications and “define.xml” for the Electronic 
Common Technical Document. In spite of the use of these standards are recommended, these models have 
not been mandated. Additionally, Study Data Specifications provide other useful technical instructions for 
submitting clinical and non-clinical data, as CDISC standards strictly complies with file format and 
variable/data size.(25) 
The transport file format used in product application for FDA is the “SAS XPORT”, known as “Version 5 SAS”, 
which is an open format. Thus, data in this format can be converted to and from this SAS transport format 
to other commonly used formats without the use of programs from SAS Institute or other specific vendors. 
The maximum size of variables and data is as follows:(25) 
Table 8 - Maximum size of  variables and data(25) 
Element  Maximum Length in Characters  
Variable Name 8 
Variable Descriptive Label  40 
Dataset Label  40 
Data  200* 
 
*However for all datasets the maximum number of characters is 200 for data values, the allocated 
character number should be the maximum length used in the values collected. For example, if the Subject 
Identification field has a maximum of 18 characters, then, when building the database, the length should 
not be set to 200 but to 18 for that field. This procedure allows reducing dataset file sizes.  
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4.4 CDISC Standards Implementation  
 
Eurotrials’ Clinical Data Management Department is now piloting the implementation of SDTM, 
“define.xml” and CDISC terminology in completed legacy clinical studies phase I and phase II of the same 
investigational product. Legacy studies are studies that were conducted without taking into consideration 
CDISC standards. 
However, the Eurotrials’ implementation of these standards started with a late legacy studies conversion, 
being  the  ultimate objective, to implement CDISC standards in new studies earlier in clinical development 
of investigational products in order to usufruct from the benefits of standards usage. 
 
Eurotrials’ implementation of CDISC standards on legacy data is performed in four phases: 
 
Phase 1 – Process and Data Review  
All databases from the different clinical trials, as well study protocols, annotated CRFs and data 
management plans were collected and compiled with the objectives of creating an inventory of the 
documentation and its posterior review. The goal of this review is to analyze the gap between non-
normalized datasets against the CDISC SDTM model and identify the disparate definitions. 
 
Phase 2 – Detailed Analysis and Design 
After the revision of the compiled documentation, it is defined for each clinical study the necessary data 
transformations and migration to normalize the existing datasets. The output of this definition is mapping 
the non-normalized datasets to a repository where all datasets and variables needed comply with SDTM 
rules. 
A plan to load the legacy data on the new SDTM datasets following the proposed mapping will then be 
performed, this plan will also include the intended tools and software to be used as well any validation 
required regarding the software. 
This phase is the most consuming one and is of vital importance to the success of CDISC standards 
implementation. 
 
Phase 3 – Implement Tools 
It is performed in a small scale the transformation and migration plan using the defined and validated tools. 
The converted datasets are thoroughly reviewed in order to assess if the plan was successfully 
implemented. 
Before proceeding to the next phase, all steps and procedures need to be fully validated and all difficulties 
or bottlenecks identified. 
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Phase 4 – Production  
All data on legacy studies are transformed into SDTM datasets and the process documented. Eurotrials will 
perform a final report and prepare documentation for posterior traceability. The data is then delivered to 
the sponsor in the standard form using SAS transport files complemented with the “define.xml”. 
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Integration
Theoretical Training
Observational Training
Study "A"
Database Specification
e-CRF completion Guidelines
Study "B"
Data Entry
Data Cleaning
Edit Check Implementation
Discrepancy Management
Study "C"
Database Quality Control
Final Database
Study "D"
Data Management Plan
Study "E"
CRF Design
Database Specification
Database Design
Database Validation
Edit Check Specification
Study "F"
Database Quality Control
Final Database
Study "G"
Data Management Plan
Study "H"
CRF Design
Study "I"
CRF Design
Database Specification
Database Design
Database Validation
Edit Check Specification
CDISC Project
Literature Review
Process and Data Review
Detailed Analysis and Design
5. Curricular Training Timeline
Figure 5 - Curricular Training Timeline 
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The curricular training in Clinical Data Management started in September of 2011. The occupied position to 
perform the curricular training in the Data Management Department was the Database Operator which is in 
terms of responsibility and autonomy between the Data Manager and Data Entry Operators. Despite of 
Database Operators having fewer activities that can be performed autonomously compared to Data 
Managers, Database Operators can perform activities usually assigned to Data Managers, if these 
performed activities are then reviewed by Data Managers to assure that they were properly executed by 
Database Operators. 
 
The integration of a new collaborator at Eurotrials is performed by the Human Resource Department Staff. 
The integration procedures begin with a training in Eurotrials basic procedures and the reading of the ‘’New 
Collaborator Guide’’. 
Since Eurotrials deals with confidential documents and data, as well proprietary procedures the new 
collaborator signs a confidential agreement   to prevent the disclosure of confidential and proprietary 
information to third parties   
It is given to each collaborator a personal file, that includes its Curriculum Vitae and it is registered all the 
training performed weather its job or project specific.  
These procedures are then followed by a formally introduction of the new collaborator to the current 
collaborators from all Eurotrials departments. 
 
The training of a Database Operator starts with a job specific training in the theoretical basis of clinical trials 
and CDM activities. Eurotrials provides the bibliographic material which is composed by the Eurotrials 
Standard Operation Procedures and a set of literature, including books, guidelines, software manuals and 
tutorials. 
Followed by the job specific training every time Clinical Data Management staff is assigned to a new project 
the corresponding training activities are implemented, including training on the therapeutic area of the 
study, training on the project study protocol and CRF.  
Any training activities are recorded in the appropriate form and archived in the collaborator’s personal file. 
 
Following the initial theoretical training, an observational period of the activities performed by the CDM 
took place in order to understand the flow of clinical data and interaction between the different 
departments. 
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During the 9 months training period I actively participated in the following studies: 
Table 9 - Studies Description 
Study Description 
Study “A” Ovarian Cancer – Phase II, EDC, local, multicenter and open label 
Study “B” Ovarian Cancer – Phase II, paper-based, local, multicenter and open label  
Study “C” Osteoarthritis – Observational Study , paper-based and local 
Study “D” Ophthalmology – Phase IV, EDC, multinational and open label  
Study “E” Prostate Cancer – Phase II, EDC, local, multicenter and randomized 
Study “F” Persistent Organic Pollutants in Breast Milk - Observational Study , paper-based 
and local 
Study “G” Purple Immune Thrombocytopenia - Observational Study, paper-based and local 
Study “H” Growth Hormone Disease in Children – Phase III, local, multicenter and 
randomized 
Study “I” Prostate Cancer – Phase IV, EDC, local, multicenter and randomized 
Study “J” Implementation of SDTM, “define.xml” and CDISC terminology on legacy studies. 
 
One of the first activities executed during the curricular training was the specification of a database for the 
Study “A”. To perform this activity it was necessary to understand the e-CRF structure and design, as well 
EDC platform basic functions. Firstly it was performed the DDD which contained a list of all pages, modules, 
variables and associated codelists as well the description of the attributes of these items. To conclude the 
specification it was performed a annotation of the e-CRF was done, since this oncology study used the EDC 
platform is was necessary to extract the e-CRF pages to a paper CRF so that the annotation of the pages, 
modules, variables and codelists could be executed. The specification of database is frequently required by 
the statistician to develop the Statistical analysis plan. This activity was also performed in the “E” and “I” 
studies 
 
In Study “A” it was necessary to create an e-CRF completion guideline that could be provided to the clinical 
investigators and monitors. To perform this task it was necessary a serious training to the EDC platform to 
ensure that the necessary features were clearly explained. The key topics explained in this document were 
the process of obtaining a valid user and password, the log-in process, creation and management of 
patients, data capture and discrepancy management.  
 
It was on Study “B” that I had the first contact with CDMS. I performed DEO activities for this study and 
introduced CRF laboratory data in the database via CDMS. Since in this study was paper-based all data were 
introduced by double data entry method. As Database Operator I cleaned all discrepancies found with the 
reconciliation of the two DEO databases. 
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I have also participated in edit checks implementation in order to validate the study “B”. The majority of the 
automatic edit checks were programmed by the SAS programmer. However, the remaining edit checks that 
were not programmed using SAS were implemented by me using the Excel tool. Further to the automatic 
implementation of the edit-checks I have also implemented manual checks defined at the DVP which 
required to accurately review the paper CRF.  
Any discrepancy found either by automatic or manual check was then reviewed by Data Manager. If the 
Data Manager considered that the discrepancy could not be solved internally, then the discrepancies were 
transformed into queries to be sent to the Eurotrials Clinical Monitors. I have participated in this process of 
sending DCF’s to the investigator’ site, as well I prepared the necessary documentation for DCF’s tracking 
such as transmittal forms. 
 
For studies “C” and “F” I participated in the final Database Quality Control Procedures, checking the values 
in the database with the values present on paper CRF’s and DCF’s. The values to be verified were specified 
on the QC plan. 
 
I cooperated with Data Managers responsible for the studies “D” and “G” to create the DMP, the main task 
performed by me was to extract the necessary information from the studies protocols, as well identification 
of assigned data management staff. 
 
I have participated in the development of a paper CRF draft for an EDC studies such as “E”,”H” and “I”.  The 
purpose of designing a paper CRF for a study intended to be implemented on an EDC platform is to get the 
approval of the Sponsor on which data is to be collected, how is collected and when is collected. When 
designing a CRF one of the most important steps is to carefully review the protocol as it specifies the 
primary and secondary endpoints of the study. The activity of designing a CRF is greatly supported by the 
medical writer. 
 
I had the possibility to participate from the beginning in studies “E” and “I”, these studies were from the 
same sponsor, investigating the same investigational medicine product. However from distinct phases, 
there were similarities between them. Thus, excluding CRF design, the database building, database 
validation and Edit Check specification procedures where performed in parallel in order to take advantage 
from synergies.  
My enrollment in these studies allowed me to acquire essential skills to any professional in the field of 
CDM. I have collaborated in the database construction for both studies, since the databases were built 
using the CDMS my knowledge in this software greatly increased. The built database reflected the CRF draft 
approved by the sponsor. As said previously I also performed the database definition for these studies. 
Other important task learned with these studies was how to build a DVP and how to specify an edit-check. 
To perform this activity it is of extreme importance a good knowledge in the study protocol and CRF, as it is 
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the only way to cross relevant data from the CRF and guarantee that the procedures planned on the study 
protocol were followed. 
My last task in both these studies was to validate the built databases, this task only occurred when the 
programmer concluded the set-up of the EDC system. Through the EDC platform it was verified if the 
behavior of the variables was the behavior that was previously specified.  The final aim of database 
validation is to transfer the study set-up form test environment to production environment. 
 
In April, I was integrated in the Eurotrial’s team responsible to implement the CDISC standards. Prior to go 
hands-on the job, it was necessary to understand the concept of the existing CDISC models. The available 
CDISC literature is extensive and additionally to the official literature there are conferences materials that 
provide further enlightenment with real cases of CDISC implementation.  
At the time of curricular training conclusion, the step 1 was completed and the step 2 was ongoing. 
Although the CDISC implementation steps were sequential, the task of reviewing the literature will go along 
with the all project since the official literature defines the intended outputs of the standards 
implementation 
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6. Conclusion 
The 9-month curricular internship at Eurotrials in the Clinical Data Management Unit was a great experience 
that allowed me to learn and develop myself as a future data manager. This CRO has a great work 
environment and it’s a place where all the collaborators and trainees have the chance to stand out and 
contribute to the development of Clinical research in Portugal.  During my internship, I performed several 
data management activities that allowed me to identify this area, as the one to develop my career. I think 
that Eurotrials is a great place to develop this career and develop the required. 
 
It allowed me to develop my team working skills, by interacting with several teams and areas of expertise. 
This constant interaction and exchange of information between all the departments allows the support and 
understanding of each activity’s flow that is performed in the context of Data Management. For instance, in 
order to correctly manage the information that arises from a clinical trial several inputs are need from the 
Clinical Trials Unit. After the treatment of this data, the information is sent to Biostatistics Unit, which 
requests certain types of information in a certain format. This work flow wouldn’t be possible without the 
constant understanding and communication between all units.  
 
Among other things, one of the best ones that I realized during this internship was the preparedness that 
the Master in Pharmaceutical Medicine and the Degree in Biomedical Sciences gave me. Many topics were 
reviewed and several were applied during the internship.  
During the internship, I gained awareness of the pivotal role that CDM activities have in the drug 
development processes. It was interesting to verify the diminishing number of clinical trials performed in 
Portugal and how our working volume is shifting from Europe to central and Latin America. 
 
The work environment and the personnel is one of the greatest assets of the data management unit. The 
persons that are part of this team are the ones responsible for the good working environment which largely 
helps the learning process and development of both social and professional skills. I am also grateful for the 
professional opportunities that Eurotrials are currently giving me, there is nothing more important than 
seeing our skills and competencies recognized.  
 
After the internship I intend to continue to extend my skills and capabilities in clinical data management 
and proceed with the career progression planed by Eurotrials. 
 
An obvious hurdle with the internship was the ability to conciliate the professional activities with the 
curricular ones; however I think that I was successful at managing the activities that I needed to do. 
Nevertheless the major hurdle was the adaptation to a new reality, because most of the times it can be very 
Curricular training Report in Clinical Data Management 
 
52 
 
intimidating and may be a step back, however this was overcome with the help of my friends and co-
workers at Eurotrials.  
 
 
7. References 
 
1. Eurotrials - Scientific Consultants. 2008 [05/Dec/2012]; Available from: 
http://www.eurotrials.com/ 
2. Eurotrials. Quality Manual. 2012. 
3. Krishnankutty B, Bellary S, Kumar N, Moodahadu L. Data management in clinical research: 
An overview. Indian Journal of Pharmacology. 2012. 44(2): 168–172. 
4. Warrington S. Purpose and Design of Clinical Trials.  The Textbook in Pharmaceutical 
Medicine  
5. European Medicines Agency. Note for Guidance on General Considerations for Clinical 
Trials (CPMP/ICH/291/95). 1998.  
6. Woodcock J, Woosley R. The FDA Critical Path Initative and Its Influence on New Drug 
Development. The Annual Review of Medicine. 2008. 59:1-12. 
7. The CRO Market Outlook: Emerging Markets, Leading Players and Future Trends. Scripp 
Business Insights. 2009. 
8. Society for Clinical Data Management. Good Clinical Data Management Practices. 2011. 
9. Prokscha S. Practical Guide to Clinical Data Management. 2007. 
10. Avey M. Case Report Form Design. In: Clinical Data Management. 2000. 
11. International Conference on Harmonisation. E6(R1) - Guideline for Good Clinical Practice. 
1996. 
12. Spilker B. Guide to Clinical Trials. 1991. 
13. Wright P, Haybittle J. Design of forms for clinical trials. BMJ. 1979.  2(6190): 590–592. 
14. Waterfield E. Data Capture. In:. Clinical Data Management. 2000. 
15. Food and Drug Administration. Guidance for Industry - Part 11, Electronic Records; 
Electronic Signatures - Scope and Application. (2003). 
16. Collins S. EDC and the Changing Role of the Clinical Data Manager. Data Basics. 2007. 
17. MacGarvey A. A snapshot view of Electronic Data Capture (EDC) - how far it's come, how 
far it has to go and how well it's been accepted. Innovations in Pharmaceutical Technology. 116-
118. 
18. Patel P. Data Validation. In: Clinical Data Management. 2000. 
19. Montjoie AJ. Introducing the CDISC Standards - New Efficiencies for Medical Research: CDISC. 
2009. 
20. Levine J. Data Standards For Clinical Trials. Data Basics. 2011. 
21. Clinical Data Interchange Standards Consortium. 2012 [05/Dec/2012]; Available from: 
http://www.cdisc.org/mission-and-principles. 
22. Clinical Data Interchange Standards Consortium. Study Data Tabulation Model. 2008. 
23. Clinical Data Interchange Standards Consortium. Study Data Tabulation Model 
Implementation Guide: Human Clinical Trials. 2008. 
24. Clinical Data Interchange Standards Consortium. Case Report Tabulation Data Definition 
Specification (define.xml). 2005. 
25. Food and Drug Administration. Study Data Specifications. 2012. 
 
 
